[Effect of immunomodulators of varying nature on the expression of lymphocyte markers in melanoma patients].
The influence of immunomodulators such as tactivin, thymalin, gangliin and translam on expression of lymphocyte markers in patients with melanoma was studied. It was shown in vitro that sensitivity of the lymphocyte receptors of melanoma patients to the immunomodulators was individual and depended on the initial level of the marker expression and the drug properties. Preliminary determination of sensitivity of the immunoregulatory cells to the immunomodulators lays the basis for the use of adequate immunocorrecting therapy in the complex treatment of oncologic patients. Gangliin and translam are membrane active compounds influencing the structure and function of lymphocytic membranes. They are considered as a promising class of immunomodulators with diverse spectra of immunotropic action and various fields of practical use.